Kenya Immediate Class B Registration: Thresholds, Verification and Revocation Risk
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Content verified as of October 30, 2026
1. Key takeaways
- Immediate Class B Registration (IBR) operates on a register first, verify later mechanism: once submitted through portal.pharmacyboardkenya.org the entry is registered immediately and placed on the PPB online register within 1 hour.
- An email notification is issued within 48 hours of successful submission; the fee is charged in full at successful submission.
- Three hard gates: approval by at least 3 reference regulatory agencies (RRAs); marketing for at least 4 years in 2 of those jurisdictions; no safety issues in the past 3 years and never refused or withdrawn by any reference authority, the region or Kenya for quality, performance or safety reasons.
- PPB verifies the documents afterwards and may attach registration conditions by intended use.
- The downside is asymmetric: failure to meet all conditions, or use of IBR by a non-Class B product, leads to revocation of the registration with no refund of fees.
2. Legal basis
| Instrument | Reference number | Date issued or effective | Provision | Relevance to this article |
|---|---|---|---|---|
| Guidelines for Registration of Medical Devices including In-Vitro Diagnostics | HPT/PER/HTR/GUD/011, Rev.02 | Effective January 31, 2022; review due January 1, 2027 | IBR route mechanism provisions | Immediate registration, 1-hour register entry, 48-hour notice, full fee charging, post-hoc verification, and revocation without refund |
| Pharmacy and Poisons Act | Cap. 244, Laws of Kenya | Enacted 1957, as amended | Section 3B(2)(r) | Authority to rely on foreign approvals while PPB remains independently responsible for its decisions |
| Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022 | Legal Notice No. 100 of 2022 | Made on June 8, 2022 | Sections 5(2), 5(5), 11 and 11(3) | PPB may approve or amend labeled uses and claims; rejections must state reasons; before revocation a Form 5 notice of intent must be issued with an opportunity to be heard |
| Second Schedule (Class B registration fee) | Legal Notice No. 100 of 2022 | June 8, 2022 | Second Schedule | Class B medical devices registration USD 200.00, the fee basis charged under IBR |
3. Expert insights
Insight 1: Why PPB dares to board first and check tickets later
The speed of IBR comes from inverting the process: registration precedes verification. This design is possible because the risk is transferred entirely to the applicant. The fee is charged in full at successful submission, and if post-hoc verification fails, the registration is revoked and the fee is not refunded. Although Section 3B(2)(r) authorizes PPB to rely on foreign decisions, the same provision states that PPB remains independently responsible for its decisions, and the revocation power therefore serves as the system’s safety valve. GRZAN’s note: what IBR saves is queueing time, not the burden of proof. The document package submitted should be prepared to full evaluation depth.
Insight 2: The evidentiary granularity of the three hard gates
The first gate, approval by at least 3 RRAs, requires the certificates themselves and their approved scope, not a list of approval numbers. The second gate, marketing for at least 4 years in 2 of those jurisdictions, requires objective timestamp evidence: records of first commercial sale locally, the effective date of local registration, or import customs entries. The third gate, no safety issues in the past 3 years, must cover no reports of death, no reports of serious deterioration in health and no open FSCA at submission, plus a declaration of never having been refused or withdrawn. The easiest gate to lose is the second, because it demands 2 of the approving jurisdictions rather than any jurisdictions, so the approving country and the marketing country must correspond.
Insight 3: Revocation without refund is a triple loss
The visible loss is an application fee at the USD 200 level; the actual losses run three layers deep. Once the registration is revoked, the product must exit the register, and supply chain and tender arrangements must be rolled back. PPB retains a record of the revocation, and reviewers will approach any later application through other routes with that judgment in mind. The time and opportunity costs are unrecoverable. GRZAN’s assessment: when any of the three gates leaves room for doubt, choosing EBR or Abridged is safer. Their speed disadvantage is limited, and they carry no register-first-then-revoke cliff.
Insight 4: Attached conditions mean immediate does not mean complete
After verifying the documents, PPB may attach registration conditions by intended use. A register entry may therefore carry restrictions on use, on labeling or additional reporting obligations. Companies often assume that a register entry equals unrestricted market access, distribute against the full intended use, and are then corrected at verification or during market surveillance. Section 5(2) also authorizes PPB to approve or amend proprietary names, labels and promotional claims, so the power to adjust the boundary of use always rests with PPB.
4. Practical recommendations
- Run an eligibility self-check before submission. Test each of the three hard gates; if any is in doubt, switch to EBR or Abridged.
- Prepare market-entry timestamps for the matching jurisdictions. The approving country and the marketing country must match, covering 2 of those jurisdictions for at least 4 years.
- Build the dossier to full evaluation depth. Post-hoc verification consults the complete dossier; it should not be simplified because of immediate registration.
- Use it only for Class B. A non-Class B product on IBR faces revocation without refund, so fix the classification conclusion first.
- Track the entry after registration. Keep the 48-hour notification email and a screenshot of the register entry, and check for intended-use conditions.
- Prepare a revocation contingency plan. Include stock disposition, customer notification and a rerouted submission plan to avoid a forced supply break.
5. Verification checklist
- □ Are approval certificates and scope documents held from at least 3 RRAs?
- □ Can marketing for at least 4 years in 2 of those jurisdictions be evidenced?
- □ In the past 3 years, are there no death reports, no serious deterioration reports and no open FSCA?
- □ Has the product never been refused or withdrawn by any reference authority, the region or Kenya?
- □ Has the Class B classification conclusion been confirmed?
- □ Have the 48-hour notification email and register entry been retained, with any attached conditions checked?
- □ Is a stock disposition and rerouted submission plan ready for a revocation scenario?
Regulatory information verified as of October 30, 2026.
Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.
GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.
For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us